NASH treatment developers gain as rival fails in trial

Lipocine

30/09/2022 19:16

** Shares of NASH-treatment developers advance between 5%
and ~15% in afternoon trade as Intercept Pharmaceutical's
 ICPT.O  drug to treat liver scarring fails in a late-stage
study  urn:newsml:reuters.com:*:nL4N3112ZA
    ** Akero Therapeutics  AKRO.O  jumps 15.8% to $34.5, while
Madrigal Pharmaceuticals  MDGL.O  rises 5% to $66 and Lipocine
 LPCN.O  4.7% to $0.45
    ** Intercept said the drug was not statistically significant
in improving fibrosis with no worsening of NASH after 18 months
of therapy 
    ** Non-alcoholic steatohepatitis, or NASH, is a serious
progressive liver disease that is one of the fastest-growing
causes of liver transplant with no FDA-approved treatments
    ** Including session gains, AKRO stock up ~63% YTD, LPCN
down ~54% and MDGL up ~8% 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))